THURSDAY, May 10 (HealthDay News) — A new weight-loss drug that is awaiting approval from the U.S. Food and Drug Administration showed promising results in a recent international trial, researchers report.

Advisers to government health regulators late Thursday recommended that they approve sales of what would be the first new prescription weight-loss drug in the U.S. in more than a decade, despite concerns over cardiac risks. Shares of the drug’s …

USA TODAY Weight-loss drug Lorcaserin: Definite maybe in 2nd run at FDA's OKLos Angeles TimesThe proposed weight-loss drug Lorcaserin, rebuffed in its bid for Food and Drug Administration approval last October, on Thursday won a recommendation of approval from the agency's advisory committee, a major step toward winning the FDA's go-ahead to …FDA advisers recommend approving Arena weight-loss...

Sci-Tech Today FDA Panel to Mull Weight-Loss Drug — AgainMedPage TodayIn 2010, an FDA panel voted against recommending approval for lorcaserin, made by Arena Pharmaceuticals, citing a variety of concerns, including a less-than-impressive average weight loss and data from animal studies suggesting that lorcaserin …Arena shares rise on favorable diet pill reviewCBS News FDA Panel Issues Mixed Review...

WEDNESDAY, Feb. 22 (HealthDay News) — A U.S. Food and Drug Administration advisory panel gave its blessing Wednesday to a highly anticipated weight loss pill that had been rejected by health advisers once before.

USA TODAY Side effects of weight-loss drug still concern FDABoston GlobeBy Andrew Pollack The Food and Drug Administration continues to have concerns that a weight-loss drug it is reviewing for the second time can cause birth defects and heart problems, documents released by the agency yesterday show.FDA: Weight-Loss Drug Effective But Has Safety ConcernsWall Street Journal Weight-Loss Drugs Face High Hurdles...

Treatment with one class of diabetes drugs, glucagon-like peptide-1 receptor (GLP-1R) agonists, helped obese and overweight patients with and without type 2 diabetes lose weight, data indicates. All patients who were administered GLP-1 agonists …

Vivus (VVUS) said late yesterday there was an increased association between babies born with an oral cleft in mothers who took one of two drugs in the company’s weight loss treatment while pregnant.

Proactive Investors USA & Canada Vivus Data Shows Weight Loss Drug Ingredient Associated with Oral CleftsForbesVivus (VVUS) said late yesterday there was an increased association between babies born with an oral cleft in mothers who took the drug in the company's weight loss treatment while pregnant. Mothers who had taken the antiepileptic drug topiramate in …Vivus Identifies Birth Defect...

After first being turned down by the Food and Drug Administration, makers of the investigational weight-loss drug Qnexa have promising new data to report and will ask less of the FDA this time around. Vivus Inc, of Mountain View, Calif., sought …